As already alluded to, infusions of GLP-1 in supraphysiological amounts or administration of GLP-1 receptor agonists are capable of inducing insulin secretion and appetite reduction also in obese patients with T2DM, whereas infusions of GIP are remarkably ineffective, regardless of infusion rate (28). The gene discussed is GCG; the disease is type 2 diabetes mellitus.